Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (symbol: ATXS) is a pioneering biopharmaceutical company dedicated to developing transformative treatments for rare and niche allergic and immunological diseases. With a mission to improve the lives of patients and families impacted by these conditions, Astria Therapeutics is at the forefront of innovative medical research and development.
The company’s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein. This promising therapy is currently in preclinical development, targeting the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and severe swelling. By inhibiting plasma kallikrein, STAR-0215 aims to prevent the debilitating effects of HAE, offering hope to patients worldwide.
Astria Therapeutics is also advancing another significant product candidate, STAR-0310. This monoclonal antibody OX40 antagonist is being developed to treat atopic dermatitis (AD), an immune disorder that causes chronic skin inflammation and intense itching. Currently in preclinical development, STAR-0310 targets the immune pathways involved in AD, potentially providing relief and improved quality of life for sufferers.
Recently, Astria Therapeutics has made significant strides in its research and development efforts. The company remains committed to advancing its pipeline and exploring strategic partnerships to bring these innovative therapies to market. Financially, Astria Therapeutics continues to focus on maintaining a strong balance sheet to support its ambitious research programs and clinical trials.
In addition to its core projects, Astria Therapeutics actively engages with the medical community, patient advocacy groups, and regulatory bodies to ensure its treatments meet the highest standards of efficacy and safety. By fostering these collaborations, the company aims to accelerate the delivery of breakthrough therapies to those in need.
For the latest updates on Astria Therapeutics, including news on their clinical trials, partnerships, and corporate developments, stay tuned to StockTitan.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the promotion of Andrea Matthews to Chief Business Officer, elevating her role to enhance the company’s strategic growth. Matthews, who has nearly nine years with Astria, is tasked with overseeing Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy. Her leadership is expected to drive the development of STAR-0215, a monoclonal antibody in clinical trials for treating hereditary angioedema. CEO Jill C. Milne highlighted Matthews' contributions to the company’s pivotal developments. The company focuses on creating impactful therapies for rare allergic and immunological diseases.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 39,300 shares of common stock on April 3, 2023. This grant, made under the 2022 Inducement Stock Incentive Plan, targets new employees as per Nasdaq Listing Rule 5635(c)(4). The options will have an exercise price of $12.93, equivalent to the closing stock price on the grant date. Vesting occurs over four years, with 25% vesting after the first anniversary and the remainder vesting monthly for 36 months, contingent upon continued employment. Astria focuses on rare and niche immunological diseases with its lead program, STAR-0215, targeting hereditary angioedema.
Astria Therapeutics, Inc. (NASDAQ:ATXS) provided a corporate update and financial results for Q4 2022 and the full year. The company is advancing STAR-0215 for hereditary angioedema (HAE) treatment, with promising Phase 1a results showing a potential half-life of up to 117 days. The ALPHA-STAR Phase 1b/2 trial is underway, with proof-of-concept results expected in mid-2024. As of December 31, 2022, Astria reported cash and short-term investments of $226M, ensuring operational funding through mid-2025. The net loss for Q4 was $13.3M, reflecting a slight increase from the previous year.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
What does Astria Therapeutics, Inc. specialize in?
What is STAR-0215?
What is hereditary angioedema (HAE)?
What is STAR-0310?
What is atopic dermatitis (AD)?
How is Astria Therapeutics funded?
Does Astria Therapeutics collaborate with other organizations?
How can I stay updated on Astria Therapeutics' latest developments?
What is the significance of STAR-0215 in treating HAE?
What are the benefits of STAR-0310 for atopic dermatitis patients?
